We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
12.50 | 0.76% | 1,653.00 | 1,654.00 | 1,655.00 | 1,655.50 | 1,634.00 | 1,638.50 | 3,990,601 | 16:35:15 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 13.83 | 68.14B |
Date | Subject | Author | Discuss |
---|---|---|---|
29/3/2018 11:39 | The judge in the latest Teva ruling appears to have a less-than-squeaky clean record of disclosure, according to this: One wonders whether he holds shares in the Israeli firm or other conflict of interest? | tradermichael | |
29/3/2018 11:27 | Among UK-listed pharmaceutical firms, GlaxoSmithKline (GSK) – which has a wide moat and a four-star rating – faces low exposure to US drug policy changes and represents one of the most undervalued firms in the drug area. Likewise, the majority of AstraZeneca’s (AZN) sales are derived outside the US, so the wide-moat firm faces fewer repercussions from changes to drug pricing there. But Shire (SHP), which could be the subject of a takeover bid from Japan’s Takeda, could see 2019 earnings hit by exposure to the medical benefits coverage market. | fangorn2 | |
29/3/2018 11:20 | - As for the Teva case, its demonstrates that "the law is an ass......" Does seem so doesn't it - the judge upheld that Teva had infringed the patent but according to him apparently this doesn't matter. This kind of ruling, along with moves on biosimilars threatens to disincentive the kind of risk taking that can lead to some of the most cutting edge treatments. - Its not a concern. Totally agree, their debt level is completely sustainable and in any case they have the means to substantially reduce it relatively quickly if they ever wanted to. As it is they reduced debt by over 1Bn last year. They also generate more free cash flow than suggested by the conservatively calculated figure they reported in their results. | romeike | |
29/3/2018 09:23 | Its not a concern. The extra part from Novartis bolts on to an earnings accretive deal. Overall annual sales are topping £30 billion and growing ..... analysts predict Shingrix will reach sales of $1.368 billion by 2020 | tradermichael | |
29/3/2018 09:14 | I hope this goes up just concerned about the debt levels | mj19 | |
29/3/2018 08:15 | As for the Teva case, its demonstrates that "the law is an ass......" | tradermichael | |
29/3/2018 02:43 | Mixed emotions glad it's going up, gutted if I don't get my reinvestment dividends at a good price, lol | montyhedge | |
28/3/2018 22:31 | Yeah hardly a game changer, onwards to 1570p next quarter | ny boy | |
28/3/2018 21:55 | I dont think shares plunged. I looks like the shares are up in NY Up 2.5% and another .9% after hours ? 235m is about 4p on the share so of zilch significance. | amt | |
28/3/2018 21:05 | OopsGlaxoSmithKline shares plunge on drug verdict | watfordhornet | |
28/3/2018 19:52 | That's an error on Google. Happens now and then check GSK ADR. Unfortunately Google Finance is pretty much useless now after 'improvements' , which seems to be a recurring theme with Google stuff. | romeike | |
28/3/2018 19:04 | Glaxo (GSK) To Acquire Novartis (NVS) Consumer Healthcare Business Stake For $13B - Slideshow | fangorn2 | |
28/3/2018 18:58 | Where did 1179.39 come from? | igerald | |
28/3/2018 18:54 | Pardon me if this is a silly question but:where did 1179.39 come from? | igerald | |
28/3/2018 18:54 | Pardon me if this is a silly question but:where did 1179.39 come from? | igerald | |
28/3/2018 18:03 | no i ll buy some p v r instead | billionaire1 | |
28/3/2018 17:49 | Buy beaten up Vodafone ! | abdullla | |
28/3/2018 17:23 | only down side is we wont get as many shares for our divi reinvest | billionaire1 | |
28/3/2018 17:16 | Nudging £14 on close, that'll do me :-) | losos | |
28/3/2018 17:04 | imastu pidgitaswell 28 Mar '18 - 09:03 - 17155 of 17170 Edit 0 1 0 Might also take a while to get through 1360-70, the wider market notwithstanding Or maybe not. What does he know, muppet: free stock charts from uk.advfn.com | imastu pidgitaswell | |
28/3/2018 16:46 | Breakout underway on stronger volumes, bidders ready to take out the Horlicks brand, strong sector with bid speculation mounting for Shire today. Looking forward a a nice juicy GSK quarterly divi payout on 12 April | ny boy | |
28/3/2018 15:34 | In theory no reason not to go back to 1550p. | montyhedge | |
28/3/2018 15:28 | Thats yesterdays high taken out,nice. | tim 3 | |
28/3/2018 15:20 | All coming out of the woodwork (LOL)TraderMichael Buy to 1950 unchanged | tradermichael |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions